MILFORD, MA–(Marketwired – April 14, 2016) – RenalGuard SolutionsT, Inc., an innovative renal protection company, today announced that an investigator-sponsored prospective study reported on the results of the use of RenalGuard® to protect patients undergoing transcatheter aortic valve implantation (TAVI) who were at high risk of developing Contrast-Induced Acute Kidney Injury (CI-AKI). The study, “RenalGuard System for the prevention of acute kidney injury in patients undergoing transcatheter aortic valve implantation” was published April 10, 2016 in EuroIntervention
by Gabriella Visconti, M.D., Laboratory of Interventional Cardiology and Department of Cardiology, Clinica Mediterranea, Naples, Italy.

Source: http://www.marketwired.com/mw/release.do?id=2115035&sourceType=3

This entry was posted on Thursday, April 14th, 2016 at 11:28 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.